Delivery Order SPE2DB24D1205-SPE2DB25FCZJL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency has awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens. The award, issued on July 30, 2025, represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,218.76 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors. The contract, awarded July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a $22,848.80 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,158.44 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed-price, non-set-aside delivery order represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $54,417.70 on August 14, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract action, this delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZJLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $59,336.93 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL). The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. Dupixent (dupilumab) is a prescription biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe asthma, making it a critical pharmaceutical supply for military healthcare programs. AmerisourceBergen Drug Corp's extensive federal contract portfolio demonstrates its established capability to meet DLA's pharmaceutical procurement requirements across multiple therapeutic domains. The competitively awarded delivery order reflects the contractor's ongoing role as a primary supplier within DLA's medical supply chain, supporting Defense Health Agency operations and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $59.3k | 8/8/25 |